AGIOS PHARMACEUTICALS, INC. cotiza a 30.21 USD y tiene una capitalización bursátil de $1.8B. En los últimos 12 meses ha facturado $98M con un margen de flujo de caja libre del -698.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults wi…
| Periodo | 2026-11 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.69 | $-1.69 | $-1.85 |
| Estimado | $-1.22 | $-1.66 | $-1.79 | $-1.94 |
| Sorpresa | — | -1.8% | +5.6% | +4.6% |
| Métrica | AGIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 88.3% | 57.0% | +31.2% |
| Operating Margin | -873.9% | -38.6% | -835.3% |
| Net Margin | -764.0% | -33.6% | -730.5% |
| FCF Margin | -698.3% | -13.9% | -684.5% |
| ROE | -34.6% | -40.4% | +5.8% |
| ROA | -31.8% | -32.0% | +0.2% |
| Current Ratio | 11.46 | 2.84 | +8.62 |
| Debt / Equity | — | 0.28 | — |